Dexloxiglumide | CR-2017, | CAS#119817-90-2 | CCK1 antagonist

MedKoo Cat#: 326948 | Name: Dexloxiglumide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexloxiglumide, also known as CR-2017, is a CCK1 antagonist potentially for the treatment of irritable bowel syndrome. It inhibits gastrointestinal motility and reduces gastric secretions, and despite older selective CCKA antagonists such as lorglumide and devazepide having had only limited success in trials and ultimately never making it into clinical use, dexloxiglumide is being investigated as a potential treatment for a variety of gastrointestinal problems including irritable bowel syndrome, dyspepsia, constipation and pancreatitis, and has had moderate success so far although trials are still ongoing.

Chemical Structure

Dexloxiglumide

CAS#119817-90-2

Theoretical Analysis

MedKoo Cat#: 326948

Name: Dexloxiglumide

CAS#: 119817-90-2

Chemical Formula: C21H30Cl2N2O5

Exact Mass: 460.1532

Molecular Weight: 461.38

Elemental Analysis: C, 54.67; H, 6.55; Cl, 15.37; N, 6.07; O, 17.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Dexloxiglumide; CR-2017; CR2017; CR 2017.

IUPAC/Chemical Name

(R)-4-(3,4-Dichlorobenzamido)-N-(3-methoxypropyl)-N-pentylglutaramic acid

InChi Key

QNQZBKQEIFTHFZ-GOSISDBHSA-N

InChi Code

InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1

SMILES Code

O=C(O)CC[C@@H](NC(C1=CC=C(Cl)C(Cl)=C1)=O)C(N(CCCOC)CCCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 461.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Serra J, Caballero N. Dexloxiglumide for the treatment of constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2016 Oct;17(14):1969-74. doi: 10.1080/14656566.2016.1229306. Epub 2016 Sep 8. PubMed PMID: 27590736. 2: Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propio nate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. Epub 2007 Aug 7. PubMed PMID: 17684117. 3: Persiani S, D'Amato M, Jakate A, Roy P, Wangsa J, Kapil R, Rovati LC. Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88. Review. PubMed PMID: 17112294. 4: Maselli MA, Mennuni L. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003 Sep;49(3):211-6. PubMed PMID: 16484960. 5: Jakate AS, Roy P, Patel A, Abramowitz W, Persiani S, Wangsa J, Kapil R. Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507. PubMed PMID: 16236040; PubMed Central PMCID: PMC1884936. 6: Roy P, Wangsa J, Patel A, Nolting A, Persiani S, Abramowitz W, Kapil R. The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender. Int J Clin Pharmacol Ther. 2005 Sep;43(9):444-51. PubMed PMID: 16163898. 7: Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri CE, Burton D, Thomforde G, Urrutia R, Zinsmeister AR. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol. 2005 Mar;100(3):652-63. PubMed PMID: 15743365. 8: Roy P, Jakate AS, Patel A, Abramowitz W, Wangsa J, Persiani S, Kapil R. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. J Clin Pharmacol. 2005 Mar;45(3):329-36. Erratum in: J Clin Pharmacol. 2005 May;45(5):603. PubMed PMID: 15703367. 9: Webber C, Stokes CA, Persiani S, Makovec F, McBurney A, Kapil RP, John BA, D'Amato M, Chasseaud LF. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog. Eur J Drug Metab Pharmacokinet. 2004 Jan-Mar;29(1):15-23. PubMed PMID: 15151166. 10: Hall M, Persiani S, Cheung YL, Matthews A, Cybulski ZR, Holding JD, Kapil R, D'Amato M, Makovec F, Rovati LC. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450. Biopharm Drug Dispos. 2004 May;25(4):163-76. PubMed PMID: 15108219. 11: Webber C, Stokes CA, Persiani S, Makovec F, McBurney A, Kapil RP, John BA, Houchen TL, D'Amato M, Chasseaud LF. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat. Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):201-12. PubMed PMID: 14527093. 12: Tolle-Sander S, Grill A, Joshi H, Kapil R, Persiani S, Polli JE. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. J Pharm Sci. 2003 Oct;92(10):1968-80. PubMed PMID: 14502537. 13: Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'amato M, Cybulski ZR, Chasseaud LF, Rovati LC. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica. 2003 Jun;33(6):625-41. PubMed PMID: 12851039. 14: Brodie R, Peard A, Roth A, Persiani S, Makovec F, D'Amato M. Development and validation of a bioanalytical method for the determination of the cholecystokinin type-1 (CCK(1)) receptor antagonist dexloxiglumide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 25;784(1):91-100. PubMed PMID: 12504186. 15: Varga G. Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs. 2002 Apr;3(4):621-6. Review. PubMed PMID: 12090734. 16: Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther. 2002 May;40(5):198-206. PubMed PMID: 12051571. 17: Varga G, Kisfalvi K, D'Amato M, Scarpignato C. Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. J Physiol Paris. 1997 May-Oct;91(3-5):257-64. PubMed PMID: 9403804. 18: Scarpignato C, Kisfalvi I, D'Amato M, Varga G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. PubMed PMID: 8791971.